Human Peripheral Blood CD14+ Monocytes
Product Code: IXC-10HU-008
Product Group: Peripheral Blood: Isolated Cells
Supplier: iXCells Biotechnologies
| Code | Size | Price |
|---|
| IXC-10HU-008-10M | 10 million cells/vial | £1,013.00 |
Quantity:
| IXC-10HU-008-40M | 40 million cells/vial | £1,742.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Target Species: Human
Application: Cell Culture
Shipping:
dry ice
Storage:
Liquid nitrogen
Documents
Further Information
Cell System:
Blood
Cell Type:
Immune Cells AND Hematopoietic Cells
Disease:
Normal
Organ/Tissue:
Peripheral Blood
PMID:
31757674; 29959142
References
- PubMed ID: 31757674 Zhao, Y., Lee, C. K., Lin, C., Gassen, R. B., Xu, X., Huang, Z., . . . Hui, E. (2019). Pd-l1:cd80 cis-heterodimer triggers the co-stimulatory receptor cd28 while repressing the inhibitory pd-1 and ctla-4 pathways. Immunity, 51(6). doi:10.1016/j.immuni.2019.11.003 ? Learn More
- PubMed ID: 29959142 Cho, H., Seo, Y., Loke, K. M., Kim, S., Oh, S., Kim, J., . . . Williams, D. R. (2018). Cancer-Stimulated cafs Enhance MONOCYTE differentiation AND Protumoral TAM activation via IL6 AND GM-CSF SECRETION. Clinical Cancer Research, 24(21), 5407-5421. doi:10.1158/1078-0432.ccr-18-0125 ? Learn More
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Media | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Blood Cell Culture Medium | IXC-MD-0007 | iXCells Biotechnologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||